SM04755 / Biosplice Therap - LARVOL DELTA

SM04755, a Small-Molecule Inhibitor of the Wnt Pathway, as a Potential Topical Treatment for Tendinopathy. (PubMed, J Orthop Res) - "Together, these data demonstrate that CLK2 and DYRK1A inhibition by SM04755 resulted in Wnt pathway inhibition, enhanced tenocyte differentiation and protection, and reduced inflammation. SM04755 has potential to benefit symptoms and modify disease processes in tendinopathy."

Journal • Immunology • Inflammation • Pain

[VIRTUAL] SM04755, A POTENTIAL DISEASE-MODIFYING TREATMENT FOR TENDINOPATHY, MODULATES THE WNT PATHWAY VIA INHIBITION OF CLKS AND DYRK1A (EULAR 2020) - "SM04755 inhibited CLKs and DYRK1A, which led to Wnt pathway modulation. Knockdowns of CLKs and DYRK1A, compared with control siRNA, induced tenocyte differentiation and reduced tendon-destroying proteases in tenocytes. This supports the potential disease modification of tendinopathy with SM04755."

Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Immunology • Oncology • Pain • Solid Tumor • CTNNB1 • IL1B • MMP1 • STAT3

Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer (clinicaltrials.gov) - P1; N=13; Completed; Sponsor: Samumed LLC; Suspended ➔ Completed; N=25 ➔ 13

Enrollment change • Trial completion • Biosimilar • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Pancreatic Cancer • Solid Tumor